New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
09:18 EDTAGEN, ETP, SUSS, POZN, HAE, OGXI, ATHX, GLW, YOKU, ABX, NEM, FRX, FURX, SOHU, BAC, PFE, AZNOn The Fly: Pre-market Movers
HIGHER: AstraZeneca (AZN), up 16% after Pfizer (PFE) confirms takeover offer made and turned down by company. Pfizer shares are also up 2.7% as the company says it is still interested in a potential AstraZeneca combination and is weighing its next steps... Furiex (FURX), up 31% after agreeing to be acquired by Forest labs (FRX) for $95 per share and contingent future payments... Susser (SUSS), up 37% after agreeing to be acquired by Energy Transfer Partners (ETP) for approx. $1.8B... Agenus (AGEN), up 10% after announcing collaboration and license agreement with Merck (MRK)... Yokou Toudou (YOKU), up 10% after announcing $1.22B investment led by Alibaba... Corning (GLW), up 2.7% after earnings report. DOWN AFTER EARNINGS: Sohu.com (SOHU), down 6.6%... Haemonetics (HAE), down 9.5%... ALSO LOWER: Bank of America (BAC), down 2.6% after suspending capital actions, including repurchase authorization... Newmont Mining (NEM), down 5.7% after terminating merger discussions with Barrick Gold (ABX)... Athersys (ATHX), down 56% after MultiStem therapy trial fails to show meaningful benefit... OncoGenex (OGXI), down 52% after Synergy did not meet primary endpoint in Phase 3 trial... POZEN (POZN), down 12% after drug candidates PA8140/PA32540 receive Complete Response Letter from FDA.
News For AZN;PFE;BAC;SOHU;FURX;FRX;NEM;ABX;YOKU;GLW;ATHX;OGXI;HAE;POZN;SUSS;ETP;AGEN From The Last 14 Days
Check below for free stories on AZN;PFE;BAC;SOHU;FURX;FRX;NEM;ABX;YOKU;GLW;ATHX;OGXI;HAE;POZN;SUSS;ETP;AGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 20, 2014
14:15 EDTYOKUFollow-up: Youku Tudou downgraded to Equal Weight at Morgan Stanley
Subscribe for More Information
14:11 EDTYOKUYouku Tudou downgraded to Equal Weight from Overweight at Morgan Stanley
08:38 EDTBACRevolution Lighting enters loan, security agreement with BofA
Revolution Lighting (RVLT) announced that it has entered into a three year loan and security agreement with Bank of America (BAC). The agreement allows Revolution Lighting to borrow up to $25M on a revolving basis. Borrowings under the agreement are determined on specified percentages of eligible receivables and inventory, and bear interest either on the base rate plus specified margins or at LIBOR plus specified margins, at the election of Revolution Lighting. The loan provides Revolution Lighting with favorable interest rates with an initial interest rate of 3%. The agreement contains customary covenants and restrictions typical of these agreements.
08:30 EDTPOZNPernix closes acquisition of Treximet
Subscribe for More Information
08:04 EDTPOZNPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
07:19 EDTYOKUYouku Tudou price target lowered to $24 from $27 at Brean Capital
Subscribe for More Information
August 19, 2014
18:07 EDTYOKUYouku Tudou sees Q3 revenue RMB 1.09B-RMB 1.13B
Subscribe for More Information
18:06 EDTYOKUYouku Tudou reports Q2 EPS (RMB 0.88) vs. (RMB 0.63) last year
Reports Q2 revenue RMB 958.72M vs. RMB 753.46M.
15:16 EDTYOKUNotable companies reporting after market close
Subscribe for More Information
12:51 EDTYOKUYouku Tudou technical comments ahead of results
In the prior three months the stock has been nearly flat in trading, punctuated by a few upside moves that failed to hold. A key level for the stock on the downside is at the $19 area. This has been support in the interval, and might well be tested again on a disappointment in expectations. If the $19 area breaks, the 52-week low at $17.77 would be the next likely downside objective. On a positive surprise, the $24 area is key. This has been the range high in the last three months. A move that is not strong enough to break above this level would keep the shares range bound. A breakout above, especially when viewed on a longer-term chart, would turn the longer-term trend back to bullish from neutral. Shares have been consolidating in price, basing, for the past several months. Resistance above $24 would be at $25.02. There is a large short-base in the name at 8.6% of the float short. That could add to buy-to-cover demand on a positive surprise.
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
06:20 EDTBACBofA COO transfers, senior manager assumes role, Bloomberg says
Subscribe for More Information
August 18, 2014
15:07 EDTYOKUYouku Tudou August weekly 22 straddle priced for 8.5% move into Q2
11:41 EDTPFECubist rises after report sparks takeover interest speculation
Subscribe for More Information
11:24 EDTYOKUYouku Tudou downgraded to Hold from Buy at TH Capital
Subscribe for More Information
09:35 EDTABXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN DG TSLA GILD FB ABX WFC C
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTAZN, PFECambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:47 EDTBACU.S. banks consider Ireland fitting spot for EU divisions, FT says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use